-
1
-
-
79955853698
-
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer
-
21554040 10.1586/era.11.34 1:CAS:528:DC%2BC3MXlvFGju7k%3D
-
Metro G, Crino L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011;11(5):673-82.
-
(2011)
Expert Rev Anticancer Ther
, vol.11
, Issue.5
, pp. 673-682
-
-
Metro, G.1
Crino, L.2
-
2
-
-
81155123620
-
Role of genotyping in non-small cell lung cancer treatment: Current status
-
22085382 10.2165/11597700-000000000-00000 1:CAS:528:DC%2BC38Xit1ShtL4%3D
-
Bonanno L, Favaretto A, Rugge M. Role of genotyping in non-small cell lung cancer treatment: current status. Drugs. 2011;71:2231-46.
-
(2011)
Drugs
, vol.71
, pp. 2231-2246
-
-
Bonanno, L.1
Favaretto, A.2
Rugge, M.3
-
3
-
-
84878888082
-
First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments
-
23479407 10.1007/s40265-013-0020-8
-
Liao B-C, Lin C-C, Yang JC-H. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013;73(4):357-69.
-
(2013)
Drugs
, vol.73
, Issue.4
, pp. 357-369
-
-
Liao, B.-C.1
Lin, C.-C.2
Yang, J.-H.3
-
4
-
-
79960110757
-
Afatinib (BIBW 2992) development in non-small-cell lung cancer
-
21732753 10.2217/fon.11.62 1:CAS:528:DC%2BC3MXos1SlurY%3D
-
Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 2011;7(7):817-25.
-
(2011)
Future Oncol
, vol.7
, Issue.7
, pp. 817-825
-
-
Hirsh, V.1
-
5
-
-
84879884454
-
Clinical perspective of afatinib in non-small cell lung cancer
-
23664448 10.1016/j.lungcan.2013.02.021
-
Chen X, Zhu Q, Zhu L, et al. Clinical perspective of afatinib in non-small cell lung cancer. Lung Cancer. 2013;81(2):155-61.
-
(2013)
Lung Cancer
, vol.81
, Issue.2
, pp. 155-161
-
-
Chen, X.1
Zhu, Q.2
Zhu, L.3
-
6
-
-
78650945778
-
Afatinib (BIBW-2992): A novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer
-
10.2217/thy.10.86 1:CAS:528:DC%2BC3cXhs1Sju7fO
-
Bordoni RE. Afatinib (BIBW-2992): a novel dual EGFR/HER2neu inhibitor with promising activity in non-small-cell lung cancer. Therapy. 2011;8(1):15-22.
-
(2011)
Therapy
, vol.8
, Issue.1
, pp. 15-22
-
-
Bordoni, R.E.1
-
7
-
-
84858002759
-
Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu
-
22325357 10.1016/j.lungcan.2012.01.008
-
De Grève J, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012;76(1):123-7.
-
(2012)
Lung Cancer
, vol.76
, Issue.1
, pp. 123-127
-
-
De Grève, J.1
Teugels, E.2
Geers, C.3
-
8
-
-
84869206583
-
Potential of afatinib in the treatment of patients with HER2-positive breast cancer
-
1:CAS:528:DC%2BC38XhsVCmtbzL
-
Geuna E, Montemurro F, Aglietta M, et al. Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Can Target Ther. 2012;4:131-7.
-
(2012)
Breast Can Target Ther
, vol.4
, pp. 131-137
-
-
Geuna, E.1
Montemurro, F.2
Aglietta, M.3
-
9
-
-
80051966802
-
Management of recurrent head neck cancer: Recent progress and future directions
-
21861540 10.2165/11592540-000000000-00000 1:CAS:528:DC%2BC3MXhsVKhu7zE
-
Brockstein BE. Management of recurrent head neck cancer: recent progress and future directions. Drugs. 2011;71:1551-9.
-
(2011)
Drugs
, vol.71
, pp. 1551-1559
-
-
Brockstein, B.E.1
-
11
-
-
84884614710
-
-
US Food and Drug Administration Accessed 25 July 2013
-
US Food and Drug Administration. Afatinib. 2013. http://google2.fda.gov/ search?q=cache:MSeHvczXMGkJ:www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm360574.htm+afatinib&client=FDAgov&lr=&proxystylesheet= FDAgov&output=xml-no-dtd&ie=UTF-8&site=FDAgov&access=p&oe= ISO-8859-1. Accessed 25 July 2013.
-
(2013)
Afatinib
-
-
-
12
-
-
84884613850
-
-
Boehringer Ingelheim Pharmaceuticals Inc. Accessed 25 July 2013
-
Boehringer Ingelheim Pharmaceuticals Inc. Gilotrif™ (afatinib) tablets, for oral use: US prescribing information. 2013. http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/201292s000lbl.pdf. Accessed 25 July 2013.
-
(2013)
Gilotrif™ (Afatinib) Tablets, for Oral Use: US Prescribing Information
-
-
-
13
-
-
85081799708
-
-
European Medicines Agency Accessed 29 July 2013
-
European Medicines Agency. Giotrif (afatinib). 2013. http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002280/smops/ Positive/human-smop-000570.jsp&mid=WC0b01ac058001d127&source= homeMedSearch&category=human. Accessed 29 July 2013.
-
(2013)
Giotrif (Afatinib)
-
-
-
15
-
-
84867621201
-
Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker
-
22888144 10.1124/jpet.112.197756 1:CAS:528:DC%2BC38XhsFKktbzE
-
Solca F, Dahl G, Zoephel A, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342-50.
-
(2012)
J Pharmacol Exp Ther
, vol.343
, Issue.2
, pp. 342-350
-
-
Solca, F.1
Dahl, G.2
Zoephel, A.3
-
16
-
-
49149118719
-
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
-
18408761 10.1038/onc.2008.109 1:CAS:528:DC%2BD1cXptlKnsbk%3D
-
Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702-11.
-
(2008)
Oncogene
, vol.27
, Issue.34
, pp. 4702-4711
-
-
Li, D.1
Ambrogio, L.2
Shimamura, T.3
-
17
-
-
84862791294
-
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: The effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
-
22436374 10.1186/1741-7015-10-28 1:CAS:528:DC%2BC38Xos12mtbs%3D
-
Chen G, Kronenberger P, Teugels E, et al. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.
-
(2012)
BMC Med
, vol.10
, pp. 28
-
-
Chen, G.1
Kronenberger, P.2
Teugels, E.3
-
18
-
-
84877660788
-
Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model
-
23443806 10.1158/1535-7163.MCT-12-0885 1:CAS:528:DC%2BC3sXntlSisro%3D
-
Ninomiya T, Takigawa N, Ichihara E, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther. 2013;12(5):589-97.
-
(2013)
Mol Cancer Ther
, vol.12
, Issue.5
, pp. 589-597
-
-
Ninomiya, T.1
Takigawa, N.2
Ichihara, E.3
-
19
-
-
84977500630
-
Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy
-
[abstract no. 2613]
-
Kristeleit H, Puglisi M, Middleton GW, et al. Phase II, open-label trial to assess the effect of continuous oral afatinib (BIBW 2992) at a daily dose of 50 mg on QTc, pharmacokinetics, and efficacy in relapsed or refractory solid tumors including brain metastases and glioblastoma that is not amenable to other therapy [abstract no. 2613]. J Clin Oncol. 2011;29(15 Suppl 1).
-
(2011)
J Clin Oncol.
, vol.29
, Issue.15 SUPPL. 1
-
-
Kristeleit, H.1
Puglisi, M.2
Middleton, G.W.3
-
20
-
-
84859793822
-
Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers
-
22200729 10.1007/s00280-011-1803-9 1:CAS:528:DC%2BC38XkvVCrsL4%3D
-
Stopfer P, Marzin K, Narjes H, et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol. 2012;69(4):1051-61.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, Issue.4
, pp. 1051-1061
-
-
Stopfer, P.1
Marzin, K.2
Narjes, H.3
-
21
-
-
84884736973
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
-
10.1200/JCO.2012.44.2806
-
Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013. doi: 10.1200/JCO.2012.44.2806.
-
(2013)
J Clin Oncol
-
-
Sequist, L.V.1
Yang, J.C.2
Yamamoto, N.3
-
22
-
-
84884659258
-
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung
-
[abstract no. 8016]
-
Wu YL, Zhou C, Hu CP, et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung [abstract no. 8016]. J Clin Oncol. 2013;31(15 Suppl).
-
(2013)
J Clin Oncol.
, vol.31
, Issue.15 SUPPL.
-
-
Wu, Y.L.1
Zhou, C.2
Hu, C.P.3
-
23
-
-
84884658724
-
LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations
-
[abstract no. 8061]
-
Geater SL, Zhou C, Hu CP, et al. LUX-Lung 6: patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations [abstract no. 8061]. J Clin Oncol. 2013;31(15 Suppl.).
-
(2013)
J Clin Oncol.
, vol.31
, Issue.15 SUPPL.
-
-
Geater, S.L.1
Zhou, C.2
Hu, C.P.3
-
24
-
-
84884605223
-
Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations
-
10.1200/JCO.2012.46.1764
-
Yang JC, Hirsh V, Schuler M, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013. doi: 10.1200/JCO.2012.46.1764.
-
(2013)
J Clin Oncol
-
-
Yang, J.C.1
Hirsh, V.2
Schuler, M.3
-
25
-
-
84862819699
-
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
-
22452895 10.1016/S1470-2045(12)70086-4 1:CAS:528:DC%2BC38Xmslyhsbk%3D
-
Yang JC-H, Shih J-Y, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012;13(5):539-48.
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 539-548
-
-
Yang, J.-H.1
Shih, J.-Y.2
Su, W.-C.3
-
26
-
-
84862785051
-
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
-
22452896 10.1016/S1470-2045(12)70087-6 1:CAS:528:DC%2BC38Xmslyhsbg%3D
-
Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528-38.
-
(2012)
Lancet Oncol
, vol.13
, Issue.5
, pp. 528-538
-
-
Miller, V.A.1
Hirsh, V.2
Cadranel, J.3
-
27
-
-
84873814691
-
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: Results of a randomized phase IIb/III trial (LUX-Lung 1)
-
23328549 10.1097/JTO.0b013e3182773fce 1:CAS:528:DC%2BC3sXht1KmsLs%3D
-
Hirsh V, Cadranel J, Cong XJ, et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013;8(2):229-37.
-
(2013)
J Thorac Oncol
, vol.8
, Issue.2
, pp. 229-237
-
-
Hirsh, V.1
Cadranel, J.2
Cong, X.J.3
-
28
-
-
84867078536
-
Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy
-
[abstract no. 7557]
-
Schuler MH, Planchard D, James CHY, et al. Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy [abstract no. 7557]. J Clin Oncol. 2012;30(15 Suppl).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL.
-
-
Schuler, M.H.1
Planchard, D.2
James, C.H.Y.3
-
29
-
-
84884659720
-
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients
-
[abstract no. 8063]
-
De Greve J, Moran T, Graas MP, et al. Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined non-small cell lung cancer (NSCLC) patients [abstract no. 8063]. J Clin Oncol. 2013;31(15 Suppl).
-
(2013)
J Clin Oncol.
, vol.31
, Issue.15 SUPPL.
-
-
De Greve, J.1
Moran, T.2
Graas, M.P.3
-
30
-
-
84859795661
-
Phase i study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)
-
22071596 10.1007/s00280-011-1738-1 1:CAS:528:DC%2BC38XkvVCku7c%3D
-
Murakami H, Tamura T, Takahashi T, et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol. 2012;69(4):891-9.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, Issue.4
, pp. 891-899
-
-
Murakami, H.1
Tamura, T.2
Takahashi, T.3
-
31
-
-
84884618137
-
LUX-Lung 4: A phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both
-
10.1200/JCO.2012.45.0981 23816963
-
Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013. doi: 10.1200/JCO.2012.45.0981.
-
(2013)
J Clin Oncol
-
-
Katakami, N.1
Atagi, S.2
Goto, K.3
-
32
-
-
84873677937
-
Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors
-
[abstract no. 12270] ix401
-
Janjigian YY, Smit EF, Horn L, et al. Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors [abstract no. 12270]. Ann Oncol. 2012;23 Suppl 9:ix401.
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL. 9
-
-
Janjigian, Y.Y.1
Smit, E.F.2
Horn, L.3
-
33
-
-
84884629596
-
-
Boehringer Ingelheim Inc. [ClinicalTrials.gov identifier NCT01090011] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
-
Boehringer Ingelheim Inc. Trial of BIBW 2992 (afatinib) + cetuximab in non-small cell lung cancer [ClinicalTrials.gov identifier NCT01090011] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www. clinicaltrials.gov/ct2/show/NCT01090011?term=afatinib+cetuximab&rank=2. Accessed 12 Aug 2013.
-
(2013)
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-small Cell Lung Cancer
-
-
-
35
-
-
85081799140
-
Phase II trial of afatinib as a third-line treatment for Korean patients with wild-type epidermal growth factor receptor stage IIIb/IV lung adenocarcinoma [poster]
-
28 Sep-2 Oct 2012; Vienna
-
Ahn J-H, Kim S-W, Cho B-C, et al. Phase II trial of afatinib as a third-line treatment for Korean patients with wild-type epidermal growth factor receptor stage IIIb/IV lung adenocarcinoma [poster]. 37th Congress of the European Society for Medical Oncology; 28 Sep-2 Oct 2012; Vienna.
-
37th Congress of the European Society for Medical Oncology
-
-
Ahn, J.-H.1
Kim, S.-W.2
Cho, B.-C.3
-
36
-
-
85081795717
-
LUX-Lung 8: A randomized, open-label, phase III trial of afatinib vs. Erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy
-
[abstract no. 509TiP] 28 Sep-2 Oct 2012; Vienna
-
Goss G, Lu S, Felip E, et al. LUX-Lung 8: a randomized, open-label, phase III trial of afatinib vs. erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy [abstract no. 509TiP]. 37th Congress of the European Society for Medical Oncology; 28 Sep-2 Oct 2012; Vienna.
-
37th Congress of the European Society for Medical Oncology
-
-
Goss, G.1
Lu, S.2
Felip, E.3
-
40
-
-
85081795229
-
-
National Cancer Center Korea [ClinicalTrials.gov identifier NCT01156545] US National Institutes of Health, ClinicalTrials.gov Accessed 25 July 2013
-
National Cancer Center Korea. BIBW 2992 plus simvastatin vs. BIBW 2992 in previously treated patients with advanced non-adenocarcinomatous NSCLC [ClinicalTrials.gov identifier NCT01156545] US National Institutes of Health, ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01156545? term=NCT01156545&rank=1. Accessed 25 July 2013.
-
(2012)
BIBW 2992 Plus Simvastatin Vs. BIBW 2992 in Previously Treated Patients with Advanced Non-adenocarcinomatous NSCLC
-
-
-
41
-
-
85081800144
-
-
Instituto Nacional de Cancerologia de Mexico [ClinicalTrials.gov identifier NCT01542437] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
-
Instituto Nacional de Cancerologia de Mexico. Treatment with BIBW 2992, irreversible inhibitor of EGFR and HER-2 in non small cell lung cancer (NSCLC) [ClinicalTrials.gov identifier NCT01542437] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01542437? term=afatinib&rank=51. Accessed 12 Aug 2013.
-
(2013)
Treatment with BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer (NSCLC)
-
-
-
42
-
-
85081792503
-
-
Massachusetts General Hospital [ClinicalTrials.gov identifier NCT01553942] US National Institutes of Health, ClinicalTrials.gov 2013 Accessed 12 Aug 2013
-
Massachusetts General Hospital. Afatinib with CT and RT for EGFR-mutant NSCLC [ClinicalTrials.gov identifier NCT01553942] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/ NCT01553942?term=afatinib&rank=44. Accessed 12 Aug 2013.
-
Afatinib with CT and RT for EGFR-mutant NSCLC
-
-
-
43
-
-
85081793785
-
-
Massachusetts General Hospital [ClinicalTrials.gov identifier NCT01746251] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
-
Massachusetts General Hospital. Adjuvant afatinib in stage I-III NSCLC with EGFR mutation [ClinicalTrials.gov identifier NCT01746251] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ ct2/show/NCT01746251?term=afatinib&rank=42. Accessed 12 Aug 2013.
-
(2013)
Adjuvant Afatinib in Stage I-III NSCLC with EGFR Mutation
-
-
-
44
-
-
85081801460
-
-
Samsung Medical Center [ClinicalTrials.gov identifier NCT01861223] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
-
Samsung Medical Center. Afatinib plus nimotuzumb for NSCLC [ClinicalTrials.gov identifier NCT01861223] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01861223? term=afatinib&rank=64. Accessed 12 Aug 2013.
-
(2013)
Afatinib Plus Nimotuzumb for NSCLC
-
-
-
48
-
-
85081795790
-
-
University College London [ClinicalTrials.gov identifier NCT01415011] US National Institutes of Health, ClinicalTrials.gov Accessed 12 Aug 2013
-
University College London. Efficacy and safety study of BIBW 2992 to treat lung cancer patients (TIMELY) [ClinicalTrials.gov identifier NCT01415011] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www. clinicaltrials.gov/ct2/show/NCT01415011?term=afatinib&rank=72. Accessed 12 Aug 2013.
-
(2013)
Efficacy and Safety Study of BIBW 2992 to Treat Lung Cancer Patients (TIMELY)
-
-
-
49
-
-
85081797943
-
-
Boehringer Ingelheim Pharmaceuticals [ClinicalTrials.gov identifier NCT01649284] US National Institutes of Health, ClinicalTrials.gov Accessed 25 July 2013
-
Boehringer Ingelheim Pharmaceuticals. Afatinib expanded access program [ClinicalTrials.gov identifier NCT01649284] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01649284? term=NCT01649284&rank=1. Accessed 25 July 2013.
-
(2013)
Afatinib Expanded Access Program
-
-
-
50
-
-
84868191989
-
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
-
22763464 10.1007/s10549-012-2126-1 1:CAS:528:DC%2BC38XhtFCrsrzO
-
Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012;134(3):1149-59.
-
(2012)
Breast Cancer Res Treat
, vol.134
, Issue.3
, pp. 1149-1159
-
-
Schuler, M.1
Awada, A.2
Harter, P.3
-
51
-
-
84863715765
-
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
-
22418700 10.1007/s10549-012-2003-y 1:CAS:528:DC%2BC38XpvFeqsLg%3D
-
Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133(3):1057-65.
-
(2012)
Breast Cancer Res Treat
, vol.133
, Issue.3
, pp. 1057-1065
-
-
Lin, N.U.1
Winer, E.P.2
Wheatley, D.3
-
52
-
-
84856063645
-
Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy
-
[abstract no. 1072] plus poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology; 4-8 Jun 2010; Chicago (IL)
-
Gunzer K, De Mont-Serrat H, Uttenreuther-Fischer MM, et al. Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy [abstract no. 1072]. J Clin Oncol. 2010;28(15 Suppl 1): plus poster presented at the 46th Annual Meeting of the American Society of Clinical Oncology; 4-8 Jun 2010; Chicago (IL).
-
(2010)
J Clin Oncol.
, vol.28
, Issue.15 SUPPL. 1
-
-
Gunzer, K.1
De Mont-Serrat, H.2
Uttenreuther-Fischer, M.M.3
-
53
-
-
84870635223
-
A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC)
-
[abstract no. 606]
-
Rimawi MF, Aleixo SB, Rozas AA, et al. A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC) [abstract no. 606]. J Clin Oncol. 2012;30(15 Suppl 1).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL. 1
-
-
Rimawi, M.F.1
Aleixo, S.B.2
Rozas, A.A.3
-
54
-
-
85081797497
-
LUX-Breast 1: Randomized, phase III trial of afatinib (BIBW 2992) and vinorelbine vs. Trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment
-
[abstract no. OT1-1-16]
-
Xu B, Im SA, Huang CS, et al. LUX-Breast 1: randomized, phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment [abstract no. OT1-1-16]. Cancer Res. 2012;72(24 Suppl 3).
-
(2012)
Cancer Res.
, vol.72
, Issue.24 SUPPL. 3
-
-
Xu, B.1
Im, S.A.2
Huang, C.S.3
-
55
-
-
84884621955
-
LUX-Breast 2: Phase II, Open-label Study of Oral Afatinib in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients (PTS) Who Progressed on Prior Trastuzumab And/or Lapatinib
-
[abstract no. OT1-1-17]
-
Hickish T, Mehta A, Jain M, et al. LUX-Breast 2: phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (PTS) who progressed on prior trastuzumab and/or lapatinib [abstract no. OT1-1-17]. Cancer Res. 2012;72(24 Suppl 3).
-
(2012)
Cancer Res.
, vol.72
, Issue.24 SUPPL. 3
-
-
Hickish, T.1
Mehta, A.2
Jain, M.3
-
56
-
-
84884599318
-
LUX-Breast 3: Randomized phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator's choice of treatment in patients (PTS) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy
-
[abstract no. OT1-1-15]
-
Joensuu H, Ould-Kaci M. LUX-Breast 3: randomized phase II trial of afatinib (BIBW 2992) alone or with vinorelbine versus investigator's choice of treatment in patients (PTS) with HER2-positive breast cancer (BC) with progressive brain metastases after trastuzumab and/or lapatinib-based therapy [abstract no. OT1-1-15]. Cancer Res. 2012;72(24 Suppl 3).
-
(2012)
Cancer Res.
, vol.72
, Issue.24 SUPPL. 3
-
-
Joensuu, H.1
Ould-Kaci, M.2
-
57
-
-
84884639882
-
Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC)
-
[abstract no. TPS650]
-
Swanton C, Cromer J. Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC) [abstract no. TPS650]. J Clin Oncol. 2012;30(15 Suppl 1).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL. 1
-
-
Swanton, C.1
Cromer, J.2
-
58
-
-
85081792932
-
Dual blockade with afatinib and trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy
-
(DAFNE)-GBG70 [abstract no. OT1-1-13]
-
Hanusch C, Schneeweiss A, Untch M, et al. Dual blockade with afatinib and trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy (DAFNE)-GBG70 [abstract no. OT1-1-13]. Cancer Res. 2012;72(24 Suppl 3).
-
(2012)
Cancer Res.
, vol.72
, Issue.24 SUPPL. 3
-
-
Hanusch, C.1
Schneeweiss, A.2
Untch, M.3
-
60
-
-
84885435197
-
A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: Final data [abstract no. PP101]
-
Cohen EEW, Fayette J, Cupissol D, et al. A randomized, open-label, phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck: final data [abstract no. PP101]. Eur Arch Otorhinolaryngol. 2012;269(4):1374.
-
(2012)
Eur Arch Otorhinolaryngol
, vol.269
, Issue.4
, pp. 1374
-
-
Cohen, E.E.W.1
Fayette, J.2
Cupissol, D.3
-
61
-
-
84896704289
-
LUX-Head and Neck 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy
-
[abstract no. TPS5598]
-
Machiels JPH, Licitra LF, Haddad RI, et al. LUX-Head and Neck 1: a phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy [abstract no. TPS5598]. J Clin Oncol. 2012;30(15 Suppl 1).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL. 1
-
-
Machiels, J.P.H.1
Licitra, L.F.2
Haddad, R.I.3
-
62
-
-
84884615858
-
LUX-Head and Neck 2: A randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients
-
[abstract no. TPS5599]
-
Burtness B, Bourhis J, Vermorken JB, et al. LUX-Head and Neck 2: a randomized, double-blind, placebo-controlled, phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients [abstract no. TPS5599]. J Clin Oncol. 2012;30(15 Suppl 1).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL. 1
-
-
Burtness, B.1
Bourhis, J.2
Vermorken, J.B.3
-
64
-
-
84873521765
-
A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer
-
[abstract no. e15017]
-
Janjigian YY, Ilson D, Kelsen DP, et al. A phase II study of afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory esophagogastric cancer [abstract no. e15017]. J Clin Oncol. 2012;30(15 Suppl 1).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL. 1
-
-
Janjigian, Y.Y.1
Ilson, D.2
Kelsen, D.P.3
-
65
-
-
80053583913
-
A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma
-
[abstract no. 2010]
-
Eisenstat DD, Nabors LB, Mason WP, et al. A phase II study of daily afatinib (BIBW 2992) with or without temozolomide (21/28 days) in the treatment of patients with recurrent glioblastoma [abstract no. 2010]. J Clin Oncol. 2011;29(15 Suppl 1).
-
(2011)
J Clin Oncol.
, vol.29
, Issue.15 SUPPL. 1
-
-
Eisenstat, D.D.1
Nabors, L.B.2
Mason, W.P.3
-
66
-
-
79960443101
-
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer
-
21737652 1:CAS:528:DC%2BC3MXpsVylsro%3D
-
Bouche O, Maindrault-Goebel F, Ducreux M, et al. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res. 2011;31(6):2271-81.
-
(2011)
Anticancer Res
, vol.31
, Issue.6
, pp. 2271-2281
-
-
Bouche, O.1
Maindrault-Goebel, F.2
Ducreux, M.3
-
67
-
-
84870821895
-
A phase II trial to compare BIBF 1120 or BIBW 2992 monotherapy versus a combination of sequential administration of both medications in patients with hormone refractory prostate cancer
-
[abstract no. 203] 26-28 Feb 2009; Orlando (FL)
-
Molife R, De Bono JS, Bell S. A phase II trial to compare BIBF 1120 or BIBW 2992 monotherapy versus a combination of sequential administration of both medications in patients with hormone refractory prostate cancer [abstract no. 203]. 2009 Genitourinary Cancers Symposium; 26-28 Feb 2009; Orlando (FL).
-
2009 Genitourinary Cancers Symposium
-
-
Molife, R.1
De Bono, J.S.2
Bell, S.3
-
68
-
-
85081796258
-
-
Memorial Sloan-Kettering Cancer Center [ClinicalTrials.gov identifier NCT01522768] US National Institutes of Health, ClinicalTrials.gov Accessed 29 July 2013
-
Memorial Sloan-Kettering Cancer Center. Afatinib (BIBW 2992) in patients with advanced HER2-positive trastuzumab-refractory advanced esophagogastric cancer [ClinicalTrials.gov identifier NCT01522768] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/ NCT01522768?term=afatinib+AND+gastric&rank=2. Accessed 29 July 2013.
-
(2013)
Afatinib (BIBW 2992) in Patients with Advanced HER2-positive Trastuzumab-refractory Advanced Esophagogastric Cancer
-
-
-
69
-
-
85081801129
-
-
Boehringer Ingelheim Pharmaceuticals [ClinicalTrials.gov identifier NCT00727506] US National Institutes of Health, ClinicalTrials.gov Accessed 29 July 2013
-
Boehringer Ingelheim Pharmaceuticals. BIBW 2992 (afatinib) with or without daily temozolomide in the treatment of patients with recurrent malignant glioma [ClinicalTrials.gov identifier NCT00727506] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/ NCT00727506?term=NCT00727506&rank=1. Accessed 29 July 2013.
-
(2013)
BIBW 2992 (Afatinib) with or Without Daily Temozolomide in the Treatment of Patients with Recurrent Malignant Glioma
-
-
-
72
-
-
85081794368
-
-
Hellenic Cooperative Oncology Group [ClinicalTrials.gov identifier NCT01743365] US National Institutes of Health, ClinicalTrials.gov Accessed 29 July 2013
-
Hellenic Cooperative Oncology Group. Clinical trial of chemotherapy combination cisplatin-fluorouracil-afatinib in patients with inoperable gastric cancer (A-GAPP) [ClinicalTrials.gov identifier NCT01743365] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ ct2/show/NCT01743365?term=afatinib+AND+gastric&rank=1. Accessed 29 July 2013.
-
(2013)
Clinical Trial of Chemotherapy Combination Cisplatin-fluorouracil- afatinib in Patients with Inoperable Gastric Cancer (A-GAPP)
-
-
-
73
-
-
84879551355
-
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
-
23242861 10.1007/s10637-012-9904-9 1:CAS:528:DC%2BC3sXjsleisL0%3D
-
Gordon MS, Mendelson DS, Gross M, et al. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):409-16.
-
(2013)
Invest New Drugs
, vol.31
, Issue.2
, pp. 409-416
-
-
Gordon, M.S.1
Mendelson, D.S.2
Gross, M.3
-
74
-
-
77957585027
-
Phase i trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors
-
20679611 10.1200/JCO.2009.26.7278 1:CAS:528:DC%2BC3cXht1eqsbzF
-
Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol. 2010;28(25):3965-72.
-
(2010)
J Clin Oncol
, vol.28
, Issue.25
, pp. 3965-3972
-
-
Yap, T.A.1
Vidal, L.2
Adam, J.3
-
75
-
-
84879551143
-
A phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors
-
23161335 10.1007/s10637-012-9890-y 1:CAS:528:DC%2BC3sXjsleisLk%3D
-
Marshall J, Hwang J, Eskens FALM, et al. A phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest New Drugs. 2013;31(2):399-408.
-
(2013)
Invest New Drugs
, vol.31
, Issue.2
, pp. 399-408
-
-
Marshall, J.1
Hwang, J.2
Eskens, F.3
-
76
-
-
38049038935
-
A phase i dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
-
18026190 10.1038/sj.bjc.6604108 1:CAS:528:DC%2BD1cXisF2qtg%3D%3D
-
Eskens FALM, Mom CH, Planting AST, et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer. 2008;98(1):80-5.
-
(2008)
Br J Cancer
, vol.98
, Issue.1
, pp. 80-85
-
-
Eskens, F.1
Mom, C.H.2
Planting, A.S.T.3
-
77
-
-
84879092054
-
Phase i study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
-
23161334 10.1007/s10637-012-9880-0 1:CAS:528:DC%2BC3sXnt12lsr4%3D
-
Awada AH, Dumez H, Hendlisz A, et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs. 2013;31(3):734-41.
-
(2013)
Invest New Drugs
, vol.31
, Issue.3
, pp. 734-741
-
-
Awada, A.H.1
Dumez, H.2
Hendlisz, A.3
-
78
-
-
84874096332
-
Phase i dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer
-
23414476 10.2217/fon.12.195 1:CAS:528:DC%2BC3sXis1Chs78%3D
-
Marshall J, Shapiro GI, Uttenreuther-Fischer M, et al. Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer. Future Oncol. 2013;9(2):271-81.
-
(2013)
Future Oncol
, vol.9
, Issue.2
, pp. 271-281
-
-
Marshall, J.1
Shapiro, G.I.2
Uttenreuther-Fischer, M.3
-
79
-
-
84877148074
-
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: Cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
-
23293114 10.1093/annonc/mds633 1:STN:280:DC%2BC3s3ntFCgsg%3D%3D
-
Vermorken JB, Rottey S, Ehrnrooth E, et al. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol. 2013;24(5):1392-400.
-
(2013)
Ann Oncol
, vol.24
, Issue.5
, pp. 1392-1400
-
-
Vermorken, J.B.1
Rottey, S.2
Ehrnrooth, E.3
-
80
-
-
85081796641
-
Phase i safety and tolerability of once daily oral afatinib (A) in combination with gemcitabine (G) in patients with advanced solid tumors
-
[abstract no. e13009]
-
Zanetta S, Bennouna J, Isambert N, et al. Phase I safety and tolerability of once daily oral afatinib (A) in combination with gemcitabine (G) in patients with advanced solid tumors [abstract no. e13009]. J Clin Oncol. 2012;30(15 Suppl 1).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL. 1
-
-
Zanetta, S.1
Bennouna, J.2
Isambert, N.3
-
81
-
-
84870632446
-
Phase i trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors
-
[abstract no. 3104]
-
Hollebecque A, Bahleda R, Berge Y, et al. Phase I trial to assess the safety and pharmacokinetics of afatinib and weekly vinorelbine in patients with advanced solid tumors [abstract no. 3104]. J Clin Oncol. 2012;30(15 Suppl 1).
-
(2012)
J Clin Oncol.
, vol.30
, Issue.15 SUPPL. 1
-
-
Hollebecque, A.1
Bahleda, R.2
Berge, Y.3
-
82
-
-
84884656251
-
A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis
-
[abstract no. 2523]
-
Chu QS, Sangha RS, Hotte SJ, et al. A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: final analysis [abstract no. 2523]. J Clin Oncol. 2013;31(15 Suppl 1).
-
(2013)
J Clin Oncol.
, vol.31
, Issue.15 SUPPL. 1
-
-
Chu, Q.S.1
Sangha, R.S.2
Hotte, S.J.3
|